HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.
about
Epigenetic Reprogramming of Muscle Progenitors: Inspiration for Clinical TherapiesEpigenetic regulation of persistent painClinical applications of epigenetics in cardiovascular disease: the long road aheadConcise Review: Epigenetic Regulation of Myogenesis in Health and DiseaseHistone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammationIL-1α is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity.Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protectionIn search of magic bullets: the golden age of immunotherapeutics.Polyarticular juvenile idiopathic arthritis - epidemiology and management approachesHistone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes.Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production.Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivoHistone deacetylase inhibitors for treating a spectrum of diseases not related to cancerEffects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes.Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).HDAC inhibition in lupus models.Targeting Histone Deacetylases in Diseases: Where Are We?Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis, and intracellular signaling in dendritic cellsRole of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition.Characterization of the Inflammatory Properties of Actively Released HMGB1 in Juvenile Idiopathic Arthritis.Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostatBeyond receptors and signaling: epigenetic factors in the regulation of innate immunityEpigenetic targets for reversing immune defects caused by alcohol exposure.Histone deacetylase inhibition rescues gene knockout levels achieved with integrase-defective lentiviral vectors encoding zinc-finger nucleases.Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases.Epigenetics and psoriasis.Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.The therapeutic potential of epigenetics in autoimmune diseases.Epigenetics in autoimmune diseases with focus on type 1 diabetes.Negative regulation of human mononuclear phagocyte function.Why is epigenetics important in understanding the pathogenesis of inflammatory musculoskeletal diseases?The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes.Chromatin modifications remodel cardiac gene expression.Polymers, scaffolds and bioactive molecules with therapeutic properties in osteochondral pathologies: what's new?Expression level of histone deacetylase 2 correlates with occurring of chronic obstructive pulmonary diseases.Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay.The role of bromodomain proteins in regulating gene expression.Connecting the dots from fatty acids to nonalcoholic steatohepatitis: epigenetics in the spotlight.Epigenetics of inflammatory arthritis.
P2860
Q26770102-5452BEA7-FDF4-467A-8B5F-C35A3ACB65EBQ26998380-DE9C9414-41E9-4DF1-9C10-0ECF4EE4B6F9Q27008290-D2A0F844-3810-447F-AC60-B0418F2E3DE9Q28072184-0FFEF8BD-0428-4F02-B4CA-C0ADC9A47E64Q28076052-BDF235C9-2AEC-47DE-951E-E92A98DE5AE0Q30666883-2AED624D-EDE5-4470-A520-902E98E8AAD2Q32945672-9BBCED69-BEFF-4FD6-883B-E6D7B454E914Q34356481-904BCF7C-9A42-4193-B20F-F8045C1DDF9EQ34434750-9909D66D-2819-43B7-86F5-2565D0732D30Q34975260-434BDC00-4546-473F-8D45-AF28D255F9FFQ34988095-F7FA49C7-B915-44AB-ABCA-24EDD2EB4B5CQ35002986-1F9C767C-D2C6-4986-8713-C68E864711B4Q35016934-330E169B-5CEC-4BBD-AAB6-FE6807EE674EQ35016951-3FF8D158-78C7-431B-8468-A164392212ABQ35016964-D1D3FC47-F65C-447E-87B5-45C1F4C27307Q35016969-A9CEBEBB-480D-4C3A-9415-A6DF03A7E6CBQ35016981-E3FEED0C-0B2D-4CC9-B373-F58CDD6DA455Q35821728-A6E4843F-B286-4E93-AFD2-B03C3ED0D0D8Q35879959-155FAC6C-796F-4399-9940-5643AADDF0C9Q36000612-2A847A33-DCEA-469F-B186-8B24427DB228Q36827894-3BC7CCFD-E6D1-4648-A0DB-236DCBCFE93EQ36885666-B1AC6315-BDE0-467A-ABDB-D87B1D886291Q36947305-4EACFF93-545A-42C2-AD2D-BD983BF2BE19Q37386440-B638BDF4-8990-48CC-B901-A1B3B78132D2Q37406920-6F063DEA-B7F9-4FA3-BC3F-7F68736512CEQ37838730-165F17EA-E055-4A29-A295-6CD4667F1A76Q37933446-5AB60687-63C4-4DBE-8691-F8B5DCE617AFQ37959304-681D835B-35F9-4BB2-82DF-F7CDF2148A05Q37967566-AA948460-6C5E-4A47-A488-B70F1790631CQ38062497-7EEAE7FE-DC9F-4020-87CA-4156F9A7E055Q38076049-2AC8929D-09C2-4AFC-8F25-A5F155F179E3Q38097131-19879A13-E523-4167-98B2-90BB52E0B475Q38108667-1B675D3F-5392-481D-B536-270CB6417A4CQ38210525-7B231FC0-117A-4FF6-8C51-2C22328A6F5EQ38874759-9A8967E7-FC51-4ED4-988F-084D7F3D847CQ39218813-E9011233-736E-4D22-8D6A-F2F3C78B1DC6Q41042385-65BCEDE6-4C5D-4615-8C54-69554EAF5E9CQ41887428-7FE41AF5-41D2-4A14-AAE7-36E4797509D2Q42536353-AEEBA0C7-D8F5-4B91-AC85-E3D47252FA00Q45967099-9F4C1441-67BF-4E5C-9728-808D2E264F69
P2860
HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.
@en
HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.
@nl
type
label
HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.
@en
HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.
@nl
prefLabel
HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.
@en
HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.
@nl
P2860
P1433
P1476
HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.
@en
P2093
Nemanja Damjanov
P2860
P2888
P304
P356
10.2119/MOLMED.2011.00030
P407
P577
2011-02-04T00:00:00Z
P5875
P6179
1068965361